Daxor CEO to Present at Lake Street Growth Conference

Event summary

Daxor CEO Michael Feldschuh to participate in Lake Street's BIG10 Conference on September 10, 2026
Company will host investor meetings during the event
Daxor focuses on blood volume measurement technology for high-cost medical conditions
Operates 20,000-square-foot U.S. manufacturing facility
Stock traded on Nasdaq under ticker DXR

The big picture

Daxor's focus on blood volume measurement addresses a critical gap in high-cost medical care, particularly for conditions like heart failure. The company's participation in investor conferences signals its push for broader market adoption and potential partnerships. With a 20,000-square-foot manufacturing facility, Daxor is positioning itself for accelerated growth in the diagnostics sector.

What we're watching

Market Expansion: How Daxor's participation in investor conferences will affect its market penetration and physician adoption rates
Regulatory Dynamics: Whether Daxor can sustain its FDA-cleared status while expanding its product offerings
Execution Risk: The pace at which Daxor integrates new distribution channels and sales staff to meet growth targets